Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study

T Gori, JM Burstein, S Ahmed, SES Miner… - Circulation, 2001 - Am Heart Assoc
T Gori, JM Burstein, S Ahmed, SES Miner, A Al-Hesayen, S Kelly, JD Parker
Circulation, 2001Am Heart Assoc
Background—In healthy humans, continuous treatment with nitroglycerin (GTN) causes nitric
oxide synthase dysfunction, probably through the reduced bioavailability of
tetrahydrobiopterin. Recent studies proposed that folic acid is involved in the regeneration of
tetrahydrobiopterin in different disease states. Therefore, we investigated whether folic acid
administration would prevent this phenomenon. We also sought to determine if folic acid
supplementation could prevent the development of tolerance to GTN. Methods and Results …
Background In healthy humans, continuous treatment with nitroglycerin (GTN) causes nitric oxide synthase dysfunction, probably through the reduced bioavailability of tetrahydrobiopterin. Recent studies proposed that folic acid is involved in the regeneration of tetrahydrobiopterin in different disease states. Therefore, we investigated whether folic acid administration would prevent this phenomenon. We also sought to determine if folic acid supplementation could prevent the development of tolerance to GTN.
Methods and Results On the first visit, 18 healthy male volunteers (aged 19 to 32 years) were randomized to receive either oral folic acid (10 mg once a day) or placebo for 1 week in a double-blind designed study. All subjects also received continuous transdermal GTN (0.6 mg/h). On the second visit, forearm blood flow was measured with venous occlusion strain gauge plethysmography in response to incremental infusions of acetylcholine (7.5, 15, and 30 μg/min), N-monomethyl-l-arginine (1, 2, and 4 μmol/min), and GTN (11 and 22 nmol/min). Folic acid prevented GTN-induced endothelial dysfunction, as assessed by responses to intraarterial acetylcholine and N-monomethyl-l-arginine (P<0.01). Moreover, in the subjects treated with folic acid plus transdermal GTN, responses to intraarterial GTN were significantly greater than those observed after transdermal GTN plus placebo (P<0.05).
Conclusion Our data demonstrate that supplemental folic acid prevents both nitric oxide synthase dysfunction induced by continuous GTN and nitrate tolerance in the arterial circulation of healthy volunteers. We hypothesize that the reduced bioavailability of tetrahydrobiopterin is involved in the pathogenesis of both phenomena. Our results confirm the view that oxidative stress contributes to nitrate tolerance.
Am Heart Assoc